FDA to collect information on financial disclosure requirements for clinical investigators

FDA is currently seeking public comments regarding the recordkeeping burden of compliance with 21 CFR 54. Investigators and research sponsors both have specific obligations under this section of the FDA regulations, which applies to any clinical investigation submitted to FDA in support of a marketing application.

Any comments should be submitted by August 27, 2012. Please see the Federal Register notice for more information.


Share This Post